Epstein-Barr Virus (HHV-4) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Epstein–Barr Virus pipeline market report provides a comprehensive overview on the therapeutics under development for Epstein–Barr Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epstein–Barr Virus and features dormant and discontinued projects.
Key Targets in the Epstein–Barr Virus Pipeline Drugs Market
In the Epstein–Barr Virus pipeline drugs market the key targets are Cells Expressing Latent Membrane Protein 1, Cells Expressing Latent Membrane Protein 2, Cells Expressing Latent Membrane Protein 2A, Epstein Barr Nuclear Antigen 1, Epstein Barr Virus Envelope Glycoprotein GP350, Epstein Barr Virus, Envelope Glycoprotein B, Epstein Barr Virus Envelope Glycoprotein H, Epstein Barr Virus Envelope Glycoprotein L, Exportin 1, and Programmed Cell Death Protein 1.
Epstein–Barr Virus Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Epstein–Barr Virus Pipeline Drugs Market
Cytotoxic To Cells Expressing Latent Membrane Protein 1 has the highest number of pipeline products followed by Cytotoxic To Cells Expressing Latent Membrane Protein 2, Cytotoxic To Cells Expressing Latent Membrane Protein 2A, Epstein Barr Nuclear Antigen 1 Inhibitor, Exportin 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, CD3 Agonist, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, and Cyclin Dependent Kinase 9 Inhibitor.
Epstein–Barr Virus Pipeline Drugs Market Analysis, by MoA
To get more insights on key MoA, download a free sample report
Epstein–Barr Virus Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Epstein–Barr Virus pipeline drugs market are intravenous, parenteral, oral, intramuscular, intradermal, intraperitoneal, intravenous drip, and topical. Intravenous has the maximum number of pipeline products.
Epstein–Barr Virus Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Epstein–Barr Virus Pipeline Drugs Market
The key molecule types in the Epstein–Barr Virus pipeline drugs market are cell therapy, gene-modified cell therapy, small molecule, subunit vaccine, vaccine, monoclonal antibody, mRNA vaccine, antibody, fusion protein, and protein.
Epstein–Barr Virus Pipeline Drugs Market, by Molecule Types
To get more insights on key molecule types, download a free sample report
Major Companies in the Epstein–Barr Virus Pipeline Drugs Market
The major companies in the Epstein–Barr Virus pipeline drugs market are Atara Biotherapeutics Inc, AlloVir Inc, Eutilex Co Ltd, Karyopharm Therapeutics Inc, Moderna Inc, Vironika LLC, Advenchen Laboratories LLC, Boryung ViGenCell Inc, Bristol-Myers Squibb Co, and China Immunotech Co Ltd.
Epstein–Barr Virus Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Epstein–Barr Virus Pipeline Drugs Market Overview
Key Targets | Cells Expressing Latent Membrane Protein 1, Cells Expressing Latent Membrane Protein 2, Cells Expressing Latent Membrane Protein 2A, Epstein Barr Nuclear Antigen 1, Epstein Barr Virus Envelope Glycoprotein GP350, Epstein Barr Virus, Envelope Glycoprotein B, Epstein Barr Virus Envelope Glycoprotein H, Epstein Barr Virus Envelope Glycoprotein L, Exportin 1, and Programmed Cell Death Protein 1 |
Key Mechanisms of action | Cytotoxic To Cells Expressing Latent Membrane Protein 1, Cytotoxic To Cells Expressing Latent Membrane Protein 2, Cytotoxic To Cells Expressing Latent Membrane Protein 2A, Epstein Barr Nuclear Antigen 1 Inhibitor, Exportin 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, CD3 Agonist, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, and Cyclin Dependent Kinase 9 Inhibitor |
Key Routes of Administration | Intravenous, Parenteral, Oral, Intramuscular, Intradermal, Intraperitoneal, Intravenous Drip, and Topical |
Key Molecule Types | Cell Therapy, Gene-Modified Cell Therapy, Small Molecule, Subunit Vaccine, Vaccine, Monoclonal Antibody, mRNA Vaccine, Antibody, Fusion Protein, and Protein |
Major Companies | Atara Biotherapeutics Inc, AlloVir Inc, Eutilex Co Ltd, Karyopharm Therapeutics Inc, Moderna Inc, Vironika LLC, Advenchen Laboratories LLC, Boryung ViGenCell Inc, Bristol-Myers Squibb Co, and China Immunotech Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Epstein–Barr Virus
- The pipeline guide reviews pipeline therapeutics for Epstein–Barr Virus by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Epstein–Barr Virus therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Epstein–Barr Virus therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Epstein–Barr Virus
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Epstein–Barr Virus
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Epstein–Barr Virus pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
AlloVir Inc
Atara Biotherapeutics Inc
Boryung ViGenCell Inc
Bristol-Myers Squibb Co
China Immunotech Co Ltd
Citranvi Biosciences LLC
Codiak BioSciences Inc
Elicio Therapeutics Inc
Eutilex Co Ltd
Galenbio Ltd
Geneius Biotechnology Inc
Genocea Biosciences Inc
iCELL Biotechnology Co Ltd
Immunotech Biopharm Ltd
Incyte Corp
Inmagene Biopharmaceuticals Ltd
Innovent Biologics Inc
Karyopharm Therapeutics Inc
Lion TCR Pte Ltd
ManysmarT Therapeutics Inc
Moderna Inc
Nanjing Iaso Biotherapeutics Co Ltd
Omeros Corp
OPKO Health Inc
Oxford Vacmedix UK Ltd
Replicate Bioscience Inc
Savoy Pharmaceuticals Inc
Shanghai YaKe Biotechnology Co Ltd
Stemirna Therapeutics Ltd
Viracta Therapeutics Inc
Vironika LLC
ViroStatics SRL
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Epstein–Barr Virus pipeline drugs market?
In the Epstein–Barr Virus pipeline drugs market the key targets are Cells Expressing Latent Membrane Protein 1, Cells Expressing Latent Membrane Protein 2, Cells Expressing Latent Membrane Protein 2A, Epstein Barr Nuclear Antigen 1, Epstein Barr Virus Envelope Glycoprotein GP350, Epstein Barr Virus, Envelope Glycoprotein B, Epstein Barr Virus Envelope Glycoprotein H, Epstein Barr Virus Envelope Glycoprotein L, Exportin 1, and Programmed Cell Death Protein 1.
-
What are the key mechanisms of action in the Epstein–Barr Virus pipeline drugs market?
In the Epstein–Barr Virus pipeline drugs market the key mechanisms of action are Cytotoxic To Cells Expressing Latent Membrane Protein 1, Cytotoxic To Cells Expressing Latent Membrane Protein 2, Cytotoxic To Cells Expressing Latent Membrane Protein 2A, Epstein Barr Nuclear Antigen 1 Inhibitor, Exportin 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, CD3 Agonist, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, and Cyclin Dependent Kinase 9 Inhibitor.
-
What are the key routes of administration in the Epstein–Barr Virus pipeline drugs market?
The key routes of administration in the Epstein–Barr Virus pipeline drugs market are Intravenous, Parenteral, Oral, Intramuscular, Intradermal, Intraperitoneal, Intravenous Drip, and Topical.
-
What are the key molecule types in the Epstein–Barr Virus pipeline drugs market?
The key molecule types in the Epstein–Barr Virus pipeline drugs market are Cell Therapy, Gene-Modified Cell Therapy, Small Molecule, Subunit Vaccine, Vaccine, Monoclonal Antibody, mRNA Vaccine, Antibody, Fusion Protein, and Protein.
-
What are the major companies in the Epstein–Barr Virus pipeline drugs market?
In the Epstein–Barr Virus pipeline drugs market the major companies are Atara Biotherapeutics Inc, AlloVir Inc, Eutilex Co Ltd, Karyopharm Therapeutics Inc, Moderna Inc, Vironika LLC, Advenchen Laboratories LLC, Boryung ViGenCell Inc, Bristol-Myers Squibb Co, and China Immunotech Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.